{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:31:08Z","timestamp":1779103868547,"version":"3.51.4"},"reference-count":30,"publisher":"BMJ","issue":"12","funder":[{"name":"Biotherapeutics for Cancer Treatment"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,11,1]]},"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Patients with relapsed or refractory malignancies have a poor prognosis. Immunotherapy with chimeric antigen receptor T (CAR-T) cells redirects a patient\u2019s immune cells against the tumour antigen. CAR-T cell therapy has demonstrated promise in treating patients with several haematological malignancies, including acute B-cell lymphoblastic leukaemia and B-cell lymphomas. CAR-T cell therapy for patients with other solid tumours is also being tested. Safety is an important consideration in CAR-T cell therapy given the potential for serious adverse events, including death. Previous reviews on CAR-T cell therapy have been limited in scope and methodology. Herein, we present a protocol for a systematic review to identify CAR-T cell interventional studies and examine the safety and efficacy of this therapy in patients with haematology malignancies and solid tumours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      We will search MEDLINE, including In-Process and Epub Ahead of Print, EMBASE and the Cochrane Central Register of Controlled Trials from 1946 to 22 February 2017. Studies will be screened by title, abstract and full text independently and in duplicate. Studies that report administering CAR-T cells of any chimeric antigen receptor construct targeting antigens in patients with haematological malignancies and solid tumours will be eligible for inclusion. Outcomes to be extracted will include complete response rate (primary outcome), overall response rate, overall survival, relapse and adverse events. A meta-analysis will be performed to synthesise the prevalence of outcomes reported as proportions with 95% CIs. The potential for bias within included studies will be assessed using a modified Institute of Health Economics tool. Heterogeneity of effect sizes will be determined using the Cochrane\n                      <jats:italic>\n                        I\n                        <jats:sup>2<\/jats:sup>\n                      <\/jats:italic>\n                      statistic.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The review findings will be submitted for peer-reviewed journal publication and presented at relevant conferences and scientific meetings to promote knowledge transfer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"CRD42017075331\">CRD42017075331<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2017-019321","type":"journal-article","created":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T04:30:26Z","timestamp":1514521826000},"page":"e019321","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis"],"prefix":"10.1136","volume":"7","author":[{"given":"Emma J M","family":"Grigor","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, Canada"},{"name":"School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Clinical Epidemiology Program, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"Department of Anesthesiology and Pain Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean A","family":"Fergusson","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, Canada"},{"name":"School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Clinical Epidemiology Program, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"Department of Surgery, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Haggar","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Program, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"Department of Anesthesiology and Pain Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Kekre","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, Canada"},{"name":"Clinical Epidemiology Program, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"Blood and Marrow Transplant Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold","family":"Atkins","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, Canada"},{"name":"Blood and Marrow Transplant Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"Cancer Therapeutic Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Shorr","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A","family":"Holt","sequence":"additional","affiliation":[{"name":"British Columbia Cancer Agency, Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, Canada"},{"name":"School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Clinical Epidemiology Program, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Ramsay","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, Canada"},{"name":"School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Clinical Epidemiology Program, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Seftel","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Winnipeg, Winnipeg, Manitoba, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Jonker","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, Canada"},{"name":"Division of Medical Oncology, The Ottawa Hospital, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mads","family":"Daugaard","sequence":"additional","affiliation":[{"name":"Molecular Pathology & Cell Imaging Core Facility, Vancouver Prostate Centre, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kednapa","family":"Thavorn","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Clinical Epidemiology Program, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"Institute for Clinical Evaluative Sciences, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Presseau","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Clinical Epidemiology Program, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0322-382X","authenticated-orcid":false,"given":"Manoj M","family":"Lalu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, Canada"},{"name":"Clinical Epidemiology Program, Blueprint Translational Research Group, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"},{"name":"Department of Anesthesiology and Pain Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Regenerative Medicine Program, The Ottawa Health Research Institute, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,12,29]]},"reference":[{"key":"2025120519572886000_7.12.e019321.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.36"},{"key":"2025120519572886000_7.12.e019321.2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.13792","article-title":"Current status of chimeric antigen receptor therapy for haematological malignancies","volume":"172","author":"Maude","year":"2016","journal-title":"Br J Haematol"},{"key":"2025120519572886000_7.12.e019321.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"2025120519572886000_7.12.e019321.4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"key":"2025120519572886000_7.12.e019321.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"2025120519572886000_7.12.e019321.6","doi-asserted-by":"crossref","unstructured":"Yu S , Li A , Liu Q , et al . Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol 2017;10.doi:10.1186\/s13045-017-0444-9","DOI":"10.1186\/s13045-017-0444-9"},{"key":"2025120519572886000_7.12.e019321.7","unstructured":"Garde D . Juno pulls the plug on a once-promising cancer treatment. 2017 https:\/\/www.statnews.com\/2017\/03\/01\/juno-cancer-treatment\/ (accessed 15 Jun 2017)."},{"key":"2025120519572886000_7.12.e019321.8","unstructured":"Dow Jones Institutional News. Subject of kite drug trial dies, sending stock down - market talk: Dow Jones Institutional News, 2017. (accessed 15 Jun 2017)."},{"key":"2025120519572886000_7.12.e019321.9","unstructured":"The Seattle Times, Technology. Juno therapeutics shuts down clinical trial of cancer drug after patient death. 2017 (accessed 15 Jun 2017)."},{"key":"2025120519572886000_7.12.e019321.10","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0006"},{"key":"2025120519572886000_7.12.e019321.11","doi-asserted-by":"publisher","DOI":"10.1186\/S13045-017-0400-8\/FIGURES\/6"},{"key":"2025120519572886000_7.12.e019321.12","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/180682"},{"key":"2025120519572886000_7.12.e019321.13","doi-asserted-by":"crossref","first-page":"33961","DOI":"10.18632\/oncotarget.5582","article-title":"Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"2025120519572886000_7.12.e019321.14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/ejh.12602","article-title":"Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials","volume":"96","author":"Zhu","year":"2016","journal-title":"Eur J Haematol"},{"key":"2025120519572886000_7.12.e019321.15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/imt-2016-0127","article-title":"Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review","volume":"9","author":"Anwer","year":"2017","journal-title":"Immunotherapy"},{"key":"2025120519572886000_7.12.e019321.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1895-5"},{"key":"2025120519572886000_7.12.e019321.17","unstructured":"Beall\u2019s List of Predatory Journals and Publishers. Potential, possible, or probable predatory\u00a0scholarly open\u2011access\u00a0publishers. http:\/\/beallslist.weebly.com\/ (accessed 13 Jun 2017)."},{"key":"2025120519572886000_7.12.e019321.18","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"2025120519572886000_7.12.e019321.19","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462300103150"},{"key":"2025120519572886000_7.12.e019321.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.01.021"},{"key":"2025120519572886000_7.12.e019321.21","unstructured":"Effective Practice and Organisation of Care (EPOC). Data collection form. EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services, 2013. http:\/\/epoc.cochrane.org\/epoc-specific-resources-review-authors."},{"key":"2025120519572886000_7.12.e019321.22","doi-asserted-by":"crossref","unstructured":"Nishino M , Jagannathan J , Ramaiya N , et al . Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know. Am J Roentgenol 2010.doi:10.2214\/AJR.09.4110","DOI":"10.2214\/AJR.09.4110"},{"key":"2025120519572886000_7.12.e019321.23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"2025120519572886000_7.12.e019321.24","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/14.5.353"},{"key":"2025120519572886000_7.12.e019321.25","unstructured":"Santana M , Feeney D . Institute of Health Economics. The importance of measuring health related quality of life (IHE report). Edmonton,Alta: Institute of Health Economics."},{"key":"2025120519572886000_7.12.e019321.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2015.07.010"},{"key":"2025120519572886000_7.12.e019321.27","unstructured":"Higgins JPT , Green S eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0: The Cochrane Collaboration, 2011. updated Mar 2011. www.handbook.cochrane.org."},{"key":"2025120519572886000_7.12.e019321.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2014.03.003"},{"key":"2025120519572886000_7.12.e019321.29","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"2025120519572886000_7.12.e019321.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-019321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T03:57:38Z","timestamp":1764993458000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-019321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12,29]]},"published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1136\/bmjopen-2017-019321"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-019321","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}